Cargando…
Orally administered branaplam does not impact neurogenesis in juvenile mice, rats, and dogs
Branaplam is a therapeutic agent currently in clinical development for the treatment of infants with type 1 spinal muscular atrophy (SMA). Since preclinical studies showed that branaplam had cell-cycle arrest effects, we sought to determine whether branaplam may affect postnatal cerebellar developme...
Autores principales: | Theil, Diethilde, Valdez, Reginald, Darribat, Katy, Doelemeyer, Arno, Sivasankaran, Rajeev, Hartmann, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565466/ https://www.ncbi.nlm.nih.gov/pubmed/34528068 http://dx.doi.org/10.1242/bio.058551 |
Ejemplares similares
-
Pharmacokinetics of Orally Administered GS-441524 in Dogs
por: Yan, Victoria C., et al.
Publicado: (2021) -
Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys
por: Theil, Diethilde, et al.
Publicado: (2019) -
An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion
por: Keller, Caroline Gubser, et al.
Publicado: (2022) -
Long-term and acute safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio(®) Plus) in juvenile and adult dogs
por: Riggs, Kari L., et al.
Publicado: (2021) -
Bioequivalence of Orally Administered Generic, Compounded, and Innovator‐Formulated Itraconazole in Healthy Dogs
por: Mawby, D.I., et al.
Publicado: (2013)